Title:
間葉系ＫＲＡＳ変異型がん治療剤
Document Type and Number:
Japanese Patent JP6860919
Kind Code:
B2
Abstract:
Provided is a therapeutic agent having a novel mechanism against specific KRAS mutation–type cancers. The present invention provides a therapeutic agent for mesenchymal KRAS mutation–type cancers that comprises a fibroblast growth factor receptor 1 (FGFR1) inhibitor. The therapeutic agent is optimally administered in combination with a MAPK/ERK kinase (MEK) inhibitor. The present invention also provides a mesenchymal cancer cell detection reagent and a cell type determination reagent set that can be used as companion diagnostic agents.
More Like This:
Inventors:
Hiroshi Ibi
Seiji Yano
Hidenori Kitai
Seiji Yano
Hidenori Kitai
Application Number:
JP2017551900A
Publication Date:
April 21, 2021
Filing Date:
November 16, 2016
Export Citation:
Assignee:
Kanazawa University
International Classes:
A61K31/506; A61K31/33; A61K31/352; A61K31/4439; A61K31/4523; A61K31/496; A61K31/517; A61K31/519; A61K31/713; A61K39/395; A61P35/00; A61P43/00; C12Q1/68; G01N33/53; G01N33/68
Domestic Patent References:
| JP2012522217A |
Other References:
Histopathology, (2013), 63, [3], p.157-166
Clin. Cancer Res., (2014), 20, [16], p.4193-4199
Clin. Cancer Res., (2014), 20, [16], p.4193-4199
Attorney, Agent or Firm:
Hiraki International Patent Office